Genmab A/S (GMABN) Stock Price & Analysis

GMABN Stock Chart & Stats

MX$8,284.23MX$0.00(0.00%)

At close: Oct 30

Day’s Range: MXN 8,284.23 - MXN 8,284.23
52-Week Range: MXN 3,551.20 - MXN 8,284.23
Previous Close: MXN 8,284.23
Volume: 0
Average Volume (3M): 27
Market Cap: MXN 656.30B
Enterprise Value: MXN 135.42B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 45.6
Beta: 0.38
Next Earnings: Nov 05, 2026 (Est.)
EPS Estimate: 65.66
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Genmab A/S News

Genmab price target raised to $57 from $42 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Genmab (GMAB) to $57 from $42 and keeps an Equal Weight rating on the shares. Published first on TheFly – the ultimate

2d agoGMAB GE9

Genmab price target raised to $80 from $58 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab (GMAB) to $80 from $58 and keeps a Buy rating on the shares. Published first on TheFly – the

2d agoGMAB GE9

Bicara Therapeutics downgraded to Sell at Goldman on lower ficera outlook

As previously reported, Goldman Sachs downgraded Bicara Therapeutics (BCAX) to Sell from Neutral with a price target of $8, down from $20. The firm is decreasing peak share estimates for

3d agoBCAX GMAB

Bicara Therapeutics price target lowered to $24 from $33 at Wedbush

Wedbush analyst David Nierengarten lowered the firm’s price target on Bicara Therapeutics (BCAX) to $24 from $33 and keeps an Outperform rating on the shares. Relevant to Bicara, Genmab’s (GMAB)

3d agoBCAX GMAB

Genmab price target raised to $70 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $70 from $50 and keeps a Buy rating on the shares. The company announced positive top-line results from the

3d agoGMAB GE9

Genmab rises 29.2%

Genmab (GMAB) is up 29.2%, or $13.04 to $57.71. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on

4d agoGMAB GE9

Midday Fly By: Trian offers to buy Wendy’s, Seagate reports Q1 beat

The major averages were mostly higher near noon as traders await the Federal Reserve’s interest-rate decision and earnings from Alphabet and Microsoft after the closing bell. Semiconductor stocks are providing

4d agoV BA

Genmab rises 17.5%

Genmab (GMAB) is up 17.5%, or $7.81 to $52.48. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended

4d agoGMAB GE9

Genmab announces results from Phase 3 LiGeR-HN1 trial of petosemtamab

Genmab (GMAB) announced topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor and the leucine-rich repeat containing G-protein-coupled

4d agoGMAB GE9

Genmab price target raised to DKK 3,200 from DKK 2,850 at BofA

BofA raised the firm’s price target on Genmab (GMAB) to DKK 3,200 from DKK 2,850 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate

6d agoGMAB GE9

Genmab: Advancing Oncology Assets Support Buy Rating and Unchanged $50 Price Target

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on GMAB stock, giving a Buy rating on October 19. Ram Selvaraju has given his Buy rating due to a

6d agoGMAB GE9

Genmab: Robust Oncology Data Drive Buy Rating and Price Target Increase to 3,200 DKK

Analyst Charlie Haywood of Bank of America Securities reiterated a Buy rating on Genmab A/S, boosting the price target to DKK3,200.00. Charlie Haywood has given his Buy rating due to

6d agoGMAB GE9

Genmab Maintained at Buy as DARZALEX Strength and Oncology Pipeline Support Unchanged $50 Price Target

Genmab, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $50.00

1w agoGMAB GE9

Genmab: Packed Catalyst Calendar and Late-Stage Pipeline Upside Drive Buy Rating and Price Target Increase to DKK 2,850

In a report released today, Charlie Haywood from Bank of America Securities maintained a Buy rating on Genmab A/S, with a price target of DKK2,850.00. Charlie Haywood has given his

3w agoGMAB GE9

GMABN FAQ

What was Genmab A/S’s price range in the past 12 months?

Genmab A/S lowest stock price was Mex$3551.20 and its highest was Mex$8284.23 in the past 12 months.

What is Genmab A/S’s market cap?

Genmab A/S’s market cap is Mex$656.30B.

When is Genmab A/S’s upcoming earnings report date?

Genmab A/S’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 3 days.

How were Genmab A/S’s earnings last quarter?

Genmab A/S released its earnings results on Aug 06, 2026. The company reported Mex$92.269 earnings per share for the quarter, beating the consensus estimate of Mex$66.9 by Mex$25.369.

Is Genmab A/S overvalued?

According to Wall Street analysts Genmab A/S’s price is currently Undervalued.

Does Genmab A/S pay dividends?

Genmab A/S does not currently pay dividends.

What is Genmab A/S’s EPS estimate?

Genmab A/S’s EPS estimate is 65.66.

How many shares outstanding does Genmab A/S have?

Genmab A/S has 62,405,853 shares outstanding.

What happened to Genmab A/S’s price movement after its last earnings report?

Genmab A/S reported an EPS of Mex$92.269 in its last earnings report, beating expectations of Mex$66.9. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Genmab A/S?

Currently, no hedge funds are holding shares in MX:GMABN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genmab A/S

Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S (GMABN) Earnings & Revenues

Historic Earnings Reports

GMABN Stock 12 Month Forecast

Average Price Target

MXN 9714.13▲(17.26% Upside)

Past 12 Months12 Month ForecastJan2026Oct2026

HighMXN 12.72K

AverageMXN 9.71K

LowMXN 7.07K

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Bearish
Overall Consensus	14	7
Technical Analysis	3	6
Moving Averages	11	1

Technical Analysis >

Ownership Overview

10.82% Mutual Funds
0.35% Other Institutional Investors
76.30% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

GMABN Stock Chart & Stats

Genmab A/S News

Genmab price target raised to $57 from $42 at Morgan Stanley

Genmab price target raised to $80 from $58 at Guggenheim

Bicara Therapeutics downgraded to Sell at Goldman on lower ficera outlook

Bicara Therapeutics price target lowered to $24 from $33 at Wedbush

Genmab price target raised to $70 from $50 at H.C. Wainwright

Genmab rises 29.2%

Midday Fly By: Trian offers to buy Wendy’s, Seagate reports Q1 beat

Genmab rises 17.5%

Genmab announces results from Phase 3 LiGeR-HN1 trial of petosemtamab

Genmab price target raised to DKK 3,200 from DKK 2,850 at BofA

Genmab: Advancing Oncology Assets Support Buy Rating and Unchanged $50 Price Target

Genmab: Robust Oncology Data Drive Buy Rating and Price Target Increase to 3,200 DKK

Genmab Maintained at Buy as DARZALEX Strength and Oncology Pipeline Support Unchanged $50 Price Target

Genmab: Packed Catalyst Calendar and Late-Stage Pipeline Upside Drive Buy Rating and Price Target Increase to DKK 2,850

GMABN FAQ

Company Description

Genmab A/S

Genmab A/S (GMABN) Earnings & Revenues

GMABN Stock 12 Month Forecast

Average Price Target

Technical Analysis

Overall Consensus

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium